Sanofi is here to support you and your patients.
Ask us your questions about our products, patient materials or organising a meeting.
InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo® and insulin degludec 100U/mL in people with T1DM.
InRange Clinical Summary
Download this six page clinical summary about the InRange study and learn more about the study design, the key findings and more.
InRange Study
Professor Richard Bergenstal presents the results of the InRange study. This study is the first randomised controlled trial to compare second generation basal insulin analogues Toujeo® and insulin degludec 100 U/mL. It compares adults with T1DM, using Time-in-Range (TIR) as the primary endpoint. Watch and learn about the study design and key findings.
View the guide below to find out more about the impact of time in range on your patients.
Toujeo
Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Patient Website
Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.
MAT-XU-2205633 (v3.0)
Date of Preparation: September 2023
